Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes
Top Cited Papers
Open Access
- 1 September 2008
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 57 (9) , 2461-2469
- https://doi.org/10.2337/db07-1808
Abstract
OBJECTIVE—Activation of the receptor for advanced glycation end products (RAGE) in diabetic vasculature is considered to be a key mediator of atherogenesis. This study examines the effects of deletion of RAGE on the development of atherosclerosis in the diabetic apoE−/− model of accelerated atherosclerosis. RESEARCH DESIGN AND METHODS—ApoE−/− and RAGE−/−/apoE−/− double knockout mice were rendered diabetic with streptozotocin and followed for 20 weeks, at which time plaque accumulation was assessed by en face analysis. RESULTS—Although diabetic apoE−/− mice showed increased plaque accumulation (14.9 ± 1.7%), diabetic RAGE−/−/apoE−/− mice had significantly reduced atherosclerotic plaque area (4.9 ± 0.4%) to levels not significantly different from control apoE−/− mice (4.3 ± 0.4%). These beneficial effects on the vasculature were associated with attenuation of leukocyte recruitment; decreased expression of proinflammatory mediators, including the nuclear factor-κB subunit p65, VCAM-1, and MCP-1; and reduced oxidative stress, as reflected by staining for nitrotyrosine and reduced expression of various NADPH oxidase subunits, gp91phox, p47phox, and rac-1. Both RAGE and RAGE ligands, including S100A8/A9, high mobility group box 1 (HMGB1), and the advanced glycation end product (AGE) carboxymethyllysine were increased in plaques from diabetic apoE−/− mice. Furthermore, the accumulation of AGEs and other ligands to RAGE was reduced in diabetic RAGE−/−/apoE−/− mice. CONCLUSIONS—This study provides evidence for RAGE playing a central role in the development of accelerated atherosclerosis associated with diabetes. These findings emphasize the potential utility of strategies targeting RAGE activation in the prevention and treatment of diabetic macrovascular complications.Keywords
This publication has 33 references indexed in Scilit:
- Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE–/– miceJournal of Clinical Investigation, 2008
- Lack of the Antioxidant Enzyme Glutathione Peroxidase-1 Accelerates Atherosclerosis in Diabetic Apolipoprotein E–Deficient MiceCirculation, 2007
- CD36: Implications in cardiovascular diseaseThe International Journal of Biochemistry & Cell Biology, 2007
- Posttranslationally Modified Proteins as Mediators of Sustained Intestinal InflammationThe American Journal of Pathology, 2006
- RAGE Control of Diabetic Nephropathy in a Mouse ModelDiabetes, 2006
- Receptor for Advanced Glycation End Products Is Involved in Impaired Angiogenic Response in DiabetesDiabetes, 2006
- Interactions between Renin Angiotensin System and Advanced Glycation in the KidneyJournal of the American Society of Nephrology, 2005
- Stem Cell Transplantation Reveals That Absence of Macrophage CD36 Is Protective Against AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Protein GlycationCirculation Research, 2004
- Irbesartan but Not Amlodipine Suppresses Diabetes-Associated AtherosclerosisCirculation, 2004